P&G/Wella deal
This article was originally published in The Rose Sheet
Executive Summary
Procter & Gamble will make a cash only tender offer of $65.70 (€1=$1.07) per share for Wella preference shares as part of acquisition agreement. Cash only offer will speed up the tender process and regulatory clearance, P&G says. During consumer products manufacturer's March 18 announcement it would acquire Wella, company indicated it would consider offering P&G shares to Wella's preference shareholders as alternative to cash (1"The Rose Sheet" March 24, 2003, p. 3). P&G plans to submit tender offer documentation during the week of April 7, and assuming regulatory acceptance, offer is expected to commence in late April, firm adds...
You may also be interested in...
Wella Complementary Salon Portfolio “On Strategy” For P&G - Lafley
The addition of Wella's professional hair care portfolio to Procter & Gamble's retail hair care assortment will position the Cincinnati-based consumer products marketer as a leader in salons and enhance its strategic position versus market-leading rival L'Oréal
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.